(UroToday.com) Dr. Juergen Gschwend summarized the three important abstracts in the setting of metastatic urothelial carcinoma (mUC) that were presented at the European Society of Medical Oncology (ESMO) 2020 Virtual Congress:
- LBA24 – TROPHY-U-01 Cohort 1 Final Results: A Phase 2 Study of Sacituzumab Govitecan (SG) in Metastatic Urothelial Cancer (mUC) That Has Progressed After Platinum (PLT) and Checkpoint Inhibitors (CPI) – Presented by Dr. Yohann Loriot (Villejuif, France)
- 698O – Patient-reported outcomes (PROs) from IMvigor130: a global, randomised, partially blinded Phase III study of atezolizumab (atezo) + platinum-based chemotherapy (PBC) vs. placebo (PBO) + PBC in previously untreated locally advanced or metastatic urothelial carcinoma (mUC) – presented by Dr. Aristotelis Bamias (Athens, Attiki, Greece)
- 699O – Avelumab first-line (1L) maintenance + best supportive care (BSC) vs. BSC alone for advanced urothelial carcinoma (UC): association between clinical outcomes and exploratory biomarkers. Presented by Dr. Srikala Sridhar (Toronto, Canada).